Varda Raises $250M for Space Manufacturing
Varda Space raises a $250 million Series D to scale pharmaceutical manufacturing missions in microgravity.
Varda is making one of the clearest commercial bets that space can become a manufacturing environment, not just a place for satellites.
What happened
Varda Space raised a $250 million Series D at a $1.6 billion valuation.
The round brings total funding to $598 million since the company’s 2021 founding. Varda is scaling missions to manufacture pharmaceuticals in microgravity, where certain materials and drug formulations can behave differently than they do on Earth.
The company’s ambition is to turn orbital production into a repeatable industrial process.
Why it matters
Most commercial space companies focus on launch, communications, imaging or defence.
Varda is targeting a different category: using orbit as part of the production process itself. If the company can prove repeatable mission economics, it could open a new industrial use case for space infrastructure.
The bigger picture
The space economy is slowly moving from access to space toward activity in space.
Manufacturing, logistics, servicing and insurance are all parts of that transition. Varda’s round suggests investors still see in-space production as a credible long-term market, despite the technical and regulatory complexity.